Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Furkejuvvon:

Bibliográfalaš dieđut
Publikašuvnnas:	NPJ Breast Cancer vol. 10, no. 1 (2024), p. 28
Váldodahkki:	Morganti, Stefania
Eará dahkkit:	Jin, Qingchun, Vincuilla, Julie, Buehler, Ryan, Ryan, Sean, Stokes, Samantha, Parker, Tonia, Mittendorf, Elizabeth A., King, Tari A., Weiss, Anna, Partridge, Ann H., Bychkovsky, Brittany L., Curigliano, Giuseppe, Tayob, Nabihah, Lin, Nancy U., Garber, Judy E., Tolaney, Sara M., Lynce, Filipa
Almmustuhtton:	Nature Publishing Group
Fáttát:	Genetic testing Oncology Tumors Surgery Cancer therapies Chemotherapy Breast cancer
Liŋkkat:	Citation/Abstract Full Text - PDF
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Govvádus
Abstrákta:	Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.
ISSN:	2374-4677
DOI:	10.1038/s41523-024-00632-8
Gáldu:	Health & Medical Collection